Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Research Note:CRISPR Therapeutics (CRSP) announces Registered Direct Offering (RDO) of $280 M priced at $71.50 per share

February 21, 2024

CRSP trading up at $3.73 at +4.73% at $82.45 <so far> CRSP reported its first profit in 10 quarters on Wednesday, The financing is expected to close on or about February 27, 2024, subject to customary closing conditions.

RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results

February 20, 2024

A scorecard of earnings releases of covered companies -  The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status".    

RegMed Investors (RMi) Research Note: Q4/23 earnings reporting dates, net losses, cash positions and runway outcomes

February 20, 2024

LPS (loss-per-share) releases will present challenges to share pricing with outcomes included They're coming ... 7 coming so far, 6 reporting (CRSP, IONS, SAGE, RARE, BPMC, ALNY)